Lv28
150 积分 2026-03-13 加入
TELIGAN Investigators. Telitacicept for IgA Nephropathy — Interim Analysis of a Phase 3 Trial
3天前
已关闭
Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial
6天前
已完结
Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial
6天前
已完结
Executive summary of the KDIGO 2025 Clinical Practice Guideline for the Management of Immunoglobulin A Nephropathy (IgAN) and Immunoglobulin A Vasculitis (IgAV)
6天前
已完结
KDIGO 2025 Clinical Practice Guideline for the Management of Immunoglobulin A Nephropathy (IgAN) and Immunoglobulin A Vasculitis (IgAV)
6天前
已完结
The role of complement in kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes Controversies Conference
6天前
已完结
Uraemia-induced immune senescence and clinical outcomes in chronic kidney disease patients
6天前
已完结
Immunology of the ageing kidney
7天前
已完结
Immunogenicity of a standard trivalent influenza vaccine in patients on long-term hemodialysis: an open-label trial
7天前
已完结
A comparison of responsiveness to hepatitis B vaccination in patients on hemodialysis and peritoneal dialysis
7天前
已完结
皖公网安备34019202002308
